In Friday’s Wall Street session, Kronos Bio Inc (NASDAQ:KRON) shares traded at $0.69, up 0.10% from the previous session.
KRON stock price is now -14.25% away from the 50-day moving average and -25.73% away from the 200-day moving average. The market capitalization of the company currently stands at $41.99M.
On November 14, 2024, Piper Sandler Downgraded its previous ‘Overweight’ rating to ‘Neutral’ on the stock reducing its target price from $6 to quote $1, while ‘Berenberg’ rates the stock as ‘Buy’
In other news, BISCHOFBERGER NORBERT W, PRESIDENT & CEO bought 410,848 shares of the company’s stock on Jun 27 ’24. The stock was bought for $478,843 at an average price of $1.17. Upon completion of the transaction, the PRESIDENT & CEO now directly owns 10,597,468 shares in the company, valued at $7.31 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 28 ’24, PRESIDENT & CEO BISCHOFBERGER NORBERT W bought 204,670 shares of the business’s stock. A total of $254,957 was incurred on buying the stock at an average price of $1.25. This leaves the insider owning 10,802,138 shares of the company worth $7.45 million. A total of 35.34% of the company’s stock is owned by insiders.
During the past 12 months, Kronos Bio Inc has had a low of $0.65 and a high of $1.60. As of last week, the company has a debt-to-equity ratio of 0.30, a current ratio of 12.93, and a quick ratio of 12.93. The fifty day moving average price for KRON is $0.80318 and a two-hundred day moving average price translates $0.92737 for the stock.
The latest earnings results from Kronos Bio Inc (NASDAQ: KRON) was released for 2025-03-31. The net profit margin was -701.53% and return on equity was -59.49% for KRON. The company reported revenue of $1.86 million for the quarter, compared to $2.52 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -26.03 percent.
